0001213900-24-036328.txt : 20240426 0001213900-24-036328.hdr.sgml : 20240426 20240425211755 ACCESSION NUMBER: 0001213900-24-036328 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240425 FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKANDA CORP. CENTRAL INDEX KEY: 0001888014 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41324 FILM NUMBER: 24878316 BUSINESS ADDRESS: STREET 1: 1A, 1B LEAROYD ROAD CITY: NEW ROMNEY STATE: X0 ZIP: TN28 8XU BUSINESS PHONE: 442034889514 MAIL ADDRESS: STREET 1: 77 KING STREET WEST, SUITE 400 STREET 2: C/O DENTONS CANADA LLP CITY: TORONTO STATE: A6 ZIP: M5K 0A1 6-K 1 ea0204742-6k_akanda.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2024

 

Commission File Number:  001-41324

 

AKANDA CORP.

 

(Name of registrant)

 

1a, 1b Learoyd Road 

New Romney TN28 8XU, United Kingdom

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

  ☒    Form 20-F ☐    Form 40-F  

 

 

 

 

 

EXHIBIT INDEX

 

On April 25, 2024, Akanda Corp. (the “Company”) issued a press release titled “Akanda Appoints Cooper to the Board of Directors”, a copy of which is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.

 

The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

 

Exhibit No.

 

Description

   
99.1   Press release, dated April 25, 2024.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AKANDA CORP.
  (Registrant)
     
Date:  April 25, 2024 By: /s/ Katie Field
    Name: Katie Field
    Title: Interim Chief Executive Officer and Director

 

 

2

 

 

EX-99.1 2 ea020474201ex99-1_akanda.htm PRESS RELEASE, DATED APRIL 25, 2024

Exhibit 99.1

 

AKANDA APPOINTS COOPER TO THE BOARD OF DIRECTORS

 

London, UK April 25, 2024 –Akanda Corp. (“Akanda” or the “Company”)  (NASDAQ: AKAN), an international medical cannabis company, Akanda Corp. announces the appointment of Christopher Cooper to its board of directors following the resignation of Harvinder Singh as a director.

 

Mr. Christopher Cooper has over 20 years of extensive business experience in all facets of corporate development, senior management, finance and operations, in both the private and public sectors. His experience includes spearheading growth strategies, financial reporting, quarterly and annual budgets, overseeing corporate administration, while achieving company objectives and maintaining internal cost controls. Mr. Cooper has been a director of several private and public Company’s over the last 20 years. Most recently he was a member of the board of directors of Alpha Lithium Corporation which was acquired by Tecpetrol in October 2023 for approximately CAD$313 million. Mr. Cooper was also a director of Counterpath Corporation, a Nasdaq listed company which was taken over by Alianza, Inc. in March 2021 for USD$25.6 million. He received his Bachelor of Business Administration from Hofstra University and his Master’s in Business Administration from Dowling College in New York.

 

The board would like to thank Mr. Singh for his time with the Company and wish him well in his future endeavors.

 

About Akanda Corp.

 

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK. Akanda also acquired the right to develop a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company plans to develop THC and cannabinoid (CBD) facilities at this site.

 

Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram

 

Investor Contact

 

ir@akandacorp.com

 

Cautionary Note Regarding Forward-Looking Information and Statements

 

This press release contains certain “forward-looking information” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved” and similar expressions and include statements regarding the timing and completion of the proposed offering. Forward-looking information may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.